State of the Discovery Nation 2021
Complex medicines will become as important as traditional small molecule drugs in the coming years, with market values of hundreds of billions of pounds. Pharmaceutical and biotech companies working in complex medicines in the UK include those specialising in antibody-drug conjugates, firms developing oligonucleotide therapeutics, entities focusing on proprietary delivery technologies for a range of […]
Proposed Definition of ‘Complex Medicine’
In a quest to address novel and previously intractable targets, drug discovery is undergoing a rapid transition from traditional small molecule and antibody approaches to a more diverse range of therapeutic modalities, including RNA therapeutics and antibody-drug conjugates. These exciting new approaches raise challenges as well as opportunities, with a critical need for development of […]
A roadmap for the discovery of therapeutics in healthy ageing
This report was produced in collaboration with colleagues at the Medicines Discovery Catapult, a UK SPINE partner. It is a guide to established best practice in drug discovery with a focus on interrogating the aetiology of age-associated multimorbidity. It complements the drug discovery roadmap, case studies drawn from recent clinical trials illustrate regulatory strategies for […]
MDC Connects: A Guide to Drug Discovery
26 experts from MDC and our partners give their views on the latest developments in drug discovery. Click here to read our guide.
Data Access Quick Guides – Access to the NIH Database of Genotypes and Phenotypes (dbGaP)
We have produced a series of Data Access Guides for a number of the major UK data suppliers that summarise the data they contain and how you might access it as an SME. The US National Institute of Health’s (NIH) National Center for Biotechnology Information (NCBI) is responsible for creating automated systems for storing and […]
The Issue with Tissue
About 1 million patients have consented to their samples being used specifically in research studies. There are a further 3 to 5 million samples held in tissue banks in the UK, where patients have permitted their sample to be used in future studies. However, it has been estimated that only 15% of samples donated for research are ever used. […]
Use of health data by the life sciences industry: a UK perspective
This report explores the use of health data and the barriers faced by the UK life sciences industry. It highlights the tangible steps being taken by UK stakeholders to deliver a ‘clear, credible national offer’ for the R&D community, which would be in the public interest. It also highlights areas where further joint effort is needed for the UK to be globally competitive. The report was released in collaboration with the Association of […]
State of the Discovery Nation 2019
The 2019 edition of the State of the Discovery Nation report by the Medicines Discovery Catapult and the BIA reveals a thriving service and supply sector for the UK in addition to its R&D biotech’s. It also highlights two breakthrough technologies set to influence the future of medicines discovery and maintain the UK’s global competitiveness. Key […]
Data Access Quick Guides – Clinical Practice Research Datalink (CPRD)
We have produced a series of Data Access Guides for a number of the major UK data suppliers that summarise the data they contain and how you might access it as an SME. Clinical Practice Research Datalink (CPRD) provides real-world retrospective and prospective research services based on UK population electronic medical records. Read the guide […]